What's in Checkpoint Therapeutics, Inc.'s pipeline?

Checkpoint Therapeutics, Inc. has 3 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Checkpoint Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: , AstraZeneca, Merck KGaA.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/checkpoint-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Checkpoint Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Checkpoint Therapeutics, Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Unloxcyt	COSIBELIMAB	marketed	Programmed Death Ligand-1 Blocker [EPC]	Pd-1	Oncology	2024-01-01
UNLOXCYT	COSIBELIMAB-IPDL	marketed	Programmed Death Ligand-1 Blocker [EPC]		Other

Therapeutic area mix

Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
AstraZeneca · 1 shared drug class
Merck KGaA · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Checkpoint Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Checkpoint Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/checkpoint-therapeutics-inc. Accessed 2026-06-10.